nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP2C9—brain cancer	0.552	1	CbGaD
Dapagliflozin—CYP2D6—Lomustine—brain cancer	0.0586	0.207	CbGbCtD
Dapagliflozin—CYP1A2—Carmustine—brain cancer	0.058	0.205	CbGbCtD
Dapagliflozin—CYP2D6—Hydroxyurea—brain cancer	0.0444	0.157	CbGbCtD
Dapagliflozin—CYP3A4—Temozolomide—brain cancer	0.0438	0.155	CbGbCtD
Dapagliflozin—CYP3A4—Lomustine—brain cancer	0.0373	0.132	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—brain cancer	0.0172	0.0607	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—brain cancer	0.015	0.053	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—brain cancer	0.009	0.0318	CbGbCtD
Dapagliflozin—Venous thrombosis—Carboplatin—brain cancer	0.0046	0.0664	CcSEcCtD
Dapagliflozin—Fluid overload—Carboplatin—brain cancer	0.00399	0.0577	CcSEcCtD
Dapagliflozin—SLC5A11—telencephalon—brain cancer	0.00369	0.0844	CbGeAlD
Dapagliflozin—SLC5A11—pituitary gland—brain cancer	0.003	0.0688	CbGeAlD
Dapagliflozin—SLC5A11—medulla oblongata—brain cancer	0.0029	0.0664	CbGeAlD
Dapagliflozin—Extravasation—Carboplatin—brain cancer	0.00285	0.0411	CcSEcCtD
Dapagliflozin—SLC5A11—midbrain—brain cancer	0.00265	0.0606	CbGeAlD
Dapagliflozin—SLC5A11—spinal cord—brain cancer	0.00258	0.0592	CbGeAlD
Dapagliflozin—SLC5A4—head—brain cancer	0.00253	0.0579	CbGeAlD
Dapagliflozin—SLC5A4—central nervous system—brain cancer	0.00231	0.0529	CbGeAlD
Dapagliflozin—SLC5A11—head—brain cancer	0.0023	0.0526	CbGeAlD
Dapagliflozin—SLC5A11—central nervous system—brain cancer	0.0021	0.048	CbGeAlD
Dapagliflozin—Phlebitis—Carboplatin—brain cancer	0.00209	0.0302	CcSEcCtD
Dapagliflozin—SLC5A11—cerebellum—brain cancer	0.00205	0.0469	CbGeAlD
Dapagliflozin—Neoplasm—Lomustine—brain cancer	0.00196	0.0284	CcSEcCtD
Dapagliflozin—SLC5A2—endocrine gland—brain cancer	0.00194	0.0445	CbGeAlD
Dapagliflozin—SLC5A1—pituitary gland—brain cancer	0.0019	0.0435	CbGeAlD
Dapagliflozin—SLC5A4—brain—brain cancer	0.00183	0.042	CbGeAlD
Dapagliflozin—CYP1A1—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00169	0.0325	CbGpPWpGaD
Dapagliflozin—UGT2B7—Tamoxifen metabolism—CYP2C9—brain cancer	0.00167	0.0322	CbGpPWpGaD
Dapagliflozin—SLC5A11—brain—brain cancer	0.00166	0.0381	CbGeAlD
Dapagliflozin—Neoplasm malignant—Procarbazine—brain cancer	0.00162	0.0233	CcSEcCtD
Dapagliflozin—SLC5A2—Orphan transporters—S100A10—brain cancer	0.0016	0.0307	CbGpPWpGaD
Dapagliflozin—SLC5A1—Orphan transporters—S100A10—brain cancer	0.0016	0.0307	CbGpPWpGaD
Dapagliflozin—CYP1A1—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00154	0.0296	CbGpPWpGaD
Dapagliflozin—Nocturia—Procarbazine—brain cancer	0.00149	0.0215	CcSEcCtD
Dapagliflozin—UGT2B4—endocrine gland—brain cancer	0.00136	0.031	CbGeAlD
Dapagliflozin—Renal failure—Lomustine—brain cancer	0.00119	0.0173	CcSEcCtD
Dapagliflozin—UGT2B4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.00119	0.023	CbGpPWpGaD
Dapagliflozin—Lung disorder—Temozolomide—brain cancer	0.00118	0.017	CcSEcCtD
Dapagliflozin—CYP2A6—Xenobiotics—CYP2C9—brain cancer	0.00109	0.021	CbGpPWpGaD
Dapagliflozin—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00108	0.0207	CbGpPWpGaD
Dapagliflozin—CYP2A6—Tamoxifen metabolism—CYP2C9—brain cancer	0.00105	0.0202	CbGpPWpGaD
Dapagliflozin—Blood urea increased—Hydroxyurea—brain cancer	0.00101	0.0146	CcSEcCtD
Dapagliflozin—Extravasation—Carmustine—brain cancer	0.000989	0.0143	CcSEcCtD
Dapagliflozin—CYP2D6—CYP2E1 reactions—CYP2C9—brain cancer	0.000985	0.019	CbGpPWpGaD
Dapagliflozin—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00098	0.0189	CbGpPWpGaD
Dapagliflozin—UGT1A9—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00097	0.0187	CbGpPWpGaD
Dapagliflozin—Neoplasm—Hydroxyurea—brain cancer	0.000965	0.0139	CcSEcCtD
Dapagliflozin—UGT1A9—endocrine gland—brain cancer	0.000926	0.0212	CbGeAlD
Dapagliflozin—Infection—Carboplatin—brain cancer	0.00088	0.0127	CcSEcCtD
Dapagliflozin—Angina pectoris—Procarbazine—brain cancer	0.000843	0.0122	CcSEcCtD
Dapagliflozin—CYP1A1—Xenobiotics—CYP2C9—brain cancer	0.000811	0.0156	CbGpPWpGaD
Dapagliflozin—Pollakiuria—Procarbazine—brain cancer	0.000799	0.0115	CcSEcCtD
Dapagliflozin—Vaginal infection—Temozolomide—brain cancer	0.000787	0.0114	CcSEcCtD
Dapagliflozin—Neoplasm—Carmustine—brain cancer	0.00078	0.0113	CcSEcCtD
Dapagliflozin—CYP1A1—Tamoxifen metabolism—CYP2C9—brain cancer	0.00078	0.015	CbGpPWpGaD
Dapagliflozin—Infection—Lomustine—brain cancer	0.00077	0.0111	CcSEcCtD
Dapagliflozin—Extravasation—Etoposide—brain cancer	0.000765	0.011	CcSEcCtD
Dapagliflozin—Neoplasm—Temozolomide—brain cancer	0.000754	0.0109	CcSEcCtD
Dapagliflozin—CYP2A6—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000747	0.0144	CbGpPWpGaD
Dapagliflozin—UGT2B7—endocrine gland—brain cancer	0.000747	0.0171	CbGeAlD
Dapagliflozin—Phlebitis—Carmustine—brain cancer	0.000727	0.0105	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Hydroxyurea—brain cancer	0.000726	0.0105	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Carmustine—brain cancer	0.00072	0.0104	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—S100A10—brain cancer	0.000704	0.0136	CbGpPWpGaD
Dapagliflozin—Body temperature increased—Carboplatin—brain cancer	0.0007	0.0101	CcSEcCtD
Dapagliflozin—UGT2B4—Biological oxidations—CYP2C9—brain cancer	0.000682	0.0131	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metapathway biotransformation—CYP2C9—brain cancer	0.000673	0.013	CbGpPWpGaD
Dapagliflozin—Thirst—Temozolomide—brain cancer	0.000636	0.00918	CcSEcCtD
Dapagliflozin—Hyponatraemia—Carmustine—brain cancer	0.000629	0.00908	CcSEcCtD
Dapagliflozin—Dysuria—Hydroxyurea—brain cancer	0.000626	0.00904	CcSEcCtD
Dapagliflozin—CYP2D6—hindbrain—brain cancer	0.000624	0.0143	CbGeAlD
Dapagliflozin—Body temperature increased—Lomustine—brain cancer	0.000613	0.00885	CcSEcCtD
Dapagliflozin—CYP2D6—Xenobiotics—CYP2C9—brain cancer	0.000611	0.0118	CbGpPWpGaD
Dapagliflozin—Infestation NOS—Hydroxyurea—brain cancer	0.000597	0.00862	CcSEcCtD
Dapagliflozin—Infestation—Hydroxyurea—brain cancer	0.000597	0.00862	CcSEcCtD
Dapagliflozin—CYP2D6—Tamoxifen metabolism—CYP2C9—brain cancer	0.000587	0.0113	CbGpPWpGaD
Dapagliflozin—Dehydration—Temozolomide—brain cancer	0.000563	0.00813	CcSEcCtD
Dapagliflozin—Phlebitis—Etoposide—brain cancer	0.000562	0.00812	CcSEcCtD
Dapagliflozin—Hypertension—Procarbazine—brain cancer	0.000521	0.00752	CcSEcCtD
Dapagliflozin—CYP1A2—Xenobiotics—CYP2C9—brain cancer	0.000517	0.00996	CbGpPWpGaD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—S100A10—brain cancer	0.000514	0.0099	CbGpPWpGaD
Dapagliflozin—UGT1A9—Irinotecan Pathway—APC—brain cancer	0.000498	0.00959	CbGpPWpGaD
Dapagliflozin—CYP1A2—Tamoxifen metabolism—CYP2C9—brain cancer	0.000497	0.00958	CbGpPWpGaD
Dapagliflozin—Oedema—Procarbazine—brain cancer	0.000492	0.00711	CcSEcCtD
Dapagliflozin—Dysuria—Temozolomide—brain cancer	0.000489	0.00706	CcSEcCtD
Dapagliflozin—Infection—Procarbazine—brain cancer	0.000489	0.00706	CcSEcCtD
Dapagliflozin—SLC5A4—Carbohydrate metabolism—ENO2—brain cancer	0.000486	0.00936	CbGpPWpGaD
Dapagliflozin—Pollakiuria—Temozolomide—brain cancer	0.000483	0.00698	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Procarbazine—brain cancer	0.000476	0.00687	CcSEcCtD
Dapagliflozin—Renal failure—Carmustine—brain cancer	0.000475	0.00685	CcSEcCtD
Dapagliflozin—CYP2A6—cerebellum—brain cancer	0.000471	0.0108	CbGeAlD
Dapagliflozin—ABCB1—blood vessel—brain cancer	0.000471	0.0108	CbGeAlD
Dapagliflozin—Urinary tract infection—Carmustine—brain cancer	0.000469	0.00678	CcSEcCtD
Dapagliflozin—Infestation NOS—Temozolomide—brain cancer	0.000466	0.00674	CcSEcCtD
Dapagliflozin—Infestation—Temozolomide—brain cancer	0.000466	0.00674	CcSEcCtD
Dapagliflozin—Nausea—Lomustine—brain cancer	0.00046	0.00665	CcSEcCtD
Dapagliflozin—Hypotension—Procarbazine—brain cancer	0.00046	0.00664	CcSEcCtD
Dapagliflozin—Urinary tract infection—Temozolomide—brain cancer	0.000453	0.00655	CcSEcCtD
Dapagliflozin—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000452	0.00871	CbGpPWpGaD
Dapagliflozin—CYP2A6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000446	0.00859	CbGpPWpGaD
Dapagliflozin—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000445	0.00857	CbGpPWpGaD
Dapagliflozin—Connective tissue disorder—Carmustine—brain cancer	0.000426	0.00615	CcSEcCtD
Dapagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000424	0.00816	CbGpPWpGaD
Dapagliflozin—Constipation—Procarbazine—brain cancer	0.000421	0.00608	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Temozolomide—brain cancer	0.000414	0.00597	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Temozolomide—brain cancer	0.000412	0.00594	CcSEcCtD
Dapagliflozin—Urethral disorder—Temozolomide—brain cancer	0.000411	0.00593	CcSEcCtD
Dapagliflozin—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.000399	0.00769	CbGpPWpGaD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000395	0.0057	CcSEcCtD
Dapagliflozin—Discomfort—Hydroxyurea—brain cancer	0.000393	0.00567	CcSEcCtD
Dapagliflozin—Urticaria—Procarbazine—brain cancer	0.000391	0.00564	CcSEcCtD
Dapagliflozin—CYP1A1—Arachidonic acid metabolism—CYP2C9—brain cancer	0.00039	0.00751	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—S100A10—brain cancer	0.000389	0.0075	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000389	0.0075	CbGpPWpGaD
Dapagliflozin—Body temperature increased—Procarbazine—brain cancer	0.000389	0.00562	CcSEcCtD
Dapagliflozin—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000384	0.00739	CbGpPWpGaD
Dapagliflozin—CYP2A6—brain—brain cancer	0.000383	0.00876	CbGeAlD
Dapagliflozin—Oedema—Hydroxyurea—brain cancer	0.000381	0.0055	CcSEcCtD
Dapagliflozin—Infection—Hydroxyurea—brain cancer	0.000378	0.00546	CcSEcCtD
Dapagliflozin—Malnutrition—Carmustine—brain cancer	0.000377	0.00545	CcSEcCtD
Dapagliflozin—Infestation NOS—Etoposide—brain cancer	0.000373	0.00539	CcSEcCtD
Dapagliflozin—Infestation—Etoposide—brain cancer	0.000373	0.00539	CcSEcCtD
Dapagliflozin—Skin disorder—Hydroxyurea—brain cancer	0.00037	0.00534	CcSEcCtD
Dapagliflozin—SLC5A1—Carbohydrate metabolism—ENO2—brain cancer	0.000368	0.00709	CbGpPWpGaD
Dapagliflozin—SLC5A2—Carbohydrate metabolism—ENO2—brain cancer	0.000368	0.00709	CbGpPWpGaD
Dapagliflozin—Acute coronary syndrome—Etoposide—brain cancer	0.000368	0.00531	CcSEcCtD
Dapagliflozin—Renal failure—Etoposide—brain cancer	0.000367	0.0053	CcSEcCtD
Dapagliflozin—CYP2A6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000366	0.00706	CbGpPWpGaD
Dapagliflozin—Myocardial infarction—Etoposide—brain cancer	0.000366	0.00528	CcSEcCtD
Dapagliflozin—Back pain—Carmustine—brain cancer	0.000365	0.00527	CcSEcCtD
Dapagliflozin—Malnutrition—Temozolomide—brain cancer	0.000365	0.00526	CcSEcCtD
Dapagliflozin—Hypersensitivity—Procarbazine—brain cancer	0.000363	0.00524	CcSEcCtD
Dapagliflozin—CYP2D6—brainstem—brain cancer	0.000358	0.00819	CbGeAlD
Dapagliflozin—Back pain—Temozolomide—brain cancer	0.000353	0.00509	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—DTX2—brain cancer	0.000353	0.00679	CbGpPWpGaD
Dapagliflozin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000338	0.00652	CbGpPWpGaD
Dapagliflozin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000337	0.00649	CbGpPWpGaD
Dapagliflozin—Angioedema—Temozolomide—brain cancer	0.000333	0.00481	CcSEcCtD
Dapagliflozin—CYP1A1—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000332	0.0064	CbGpPWpGaD
Dapagliflozin—Urinary tract disorder—Etoposide—brain cancer	0.000331	0.00478	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000329	0.00475	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—brain cancer	0.000328	0.00474	CcSEcCtD
Dapagliflozin—Hypertension—Carmustine—brain cancer	0.000326	0.0047	CcSEcCtD
Dapagliflozin—Constipation—Hydroxyurea—brain cancer	0.000326	0.0047	CcSEcCtD
Dapagliflozin—Dizziness—Procarbazine—brain cancer	0.000325	0.0047	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000325	0.00627	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPAR Alpha Pathway—CDK4—brain cancer	0.000322	0.00621	CbGpPWpGaD
Dapagliflozin—CYP2D6—telencephalon—brain cancer	0.000317	0.00727	CbGeAlD
Dapagliflozin—Hypertension—Temozolomide—brain cancer	0.000315	0.00454	CcSEcCtD
Dapagliflozin—UGT2B7—Biological oxidations—CYP2C9—brain cancer	0.000311	0.00599	CbGpPWpGaD
Dapagliflozin—Rash—Procarbazine—brain cancer	0.00031	0.00448	CcSEcCtD
Dapagliflozin—Dermatitis—Procarbazine—brain cancer	0.00031	0.00448	CcSEcCtD
Dapagliflozin—Headache—Procarbazine—brain cancer	0.000308	0.00445	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000308	0.00445	CcSEcCtD
Dapagliflozin—Oedema—Carmustine—brain cancer	0.000308	0.00445	CcSEcCtD
Dapagliflozin—Discomfort—Temozolomide—brain cancer	0.000307	0.00443	CcSEcCtD
Dapagliflozin—UGT2B7—Metapathway biotransformation—CYP2C9—brain cancer	0.000307	0.0059	CbGpPWpGaD
Dapagliflozin—Infection—Carmustine—brain cancer	0.000306	0.00442	CcSEcCtD
Dapagliflozin—Body temperature increased—Hydroxyurea—brain cancer	0.000301	0.00435	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Temozolomide—brain cancer	0.000298	0.0043	CcSEcCtD
Dapagliflozin—Oedema—Temozolomide—brain cancer	0.000298	0.0043	CcSEcCtD
Dapagliflozin—Infection—Temozolomide—brain cancer	0.000296	0.00427	CcSEcCtD
Dapagliflozin—Nausea—Procarbazine—brain cancer	0.000292	0.00422	CcSEcCtD
Dapagliflozin—Skin disorder—Temozolomide—brain cancer	0.000289	0.00417	CcSEcCtD
Dapagliflozin—Hypotension—Carmustine—brain cancer	0.000288	0.00415	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Temozolomide—brain cancer	0.000288	0.00415	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—brain cancer	0.000282	0.00407	CcSEcCtD
Dapagliflozin—CYP1A2—endocrine gland—brain cancer	0.000281	0.00643	CbGeAlD
Dapagliflozin—Hypersensitivity—Hydroxyurea—brain cancer	0.000281	0.00405	CcSEcCtD
Dapagliflozin—CYP1A1—endocrine gland—brain cancer	0.000277	0.00635	CbGeAlD
Dapagliflozin—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000274	0.00528	CbGpPWpGaD
Dapagliflozin—CYP1A1—head—brain cancer	0.000274	0.00627	CbGeAlD
Dapagliflozin—CYP1A1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000273	0.00526	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—DTX2—brain cancer	0.000267	0.00515	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—DTX2—brain cancer	0.000267	0.00515	CbGpPWpGaD
Dapagliflozin—CYP2C9—endocrine gland—brain cancer	0.000267	0.00611	CbGeAlD
Dapagliflozin—Gastrointestinal disorder—Carmustine—brain cancer	0.000266	0.00384	CcSEcCtD
Dapagliflozin—Constipation—Carmustine—brain cancer	0.000263	0.0038	CcSEcCtD
Dapagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000261	0.00503	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.00026	0.00502	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HES5—brain cancer	0.000259	0.00498	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Temozolomide—brain cancer	0.000257	0.00371	CcSEcCtD
Dapagliflozin—Constipation—Temozolomide—brain cancer	0.000254	0.00367	CcSEcCtD
Dapagliflozin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000254	0.00488	CbGpPWpGaD
Dapagliflozin—UGT1A9—Biological oxidations—CYP2C9—brain cancer	0.000253	0.00486	CbGpPWpGaD
Dapagliflozin—Hypertension—Etoposide—brain cancer	0.000252	0.00364	CcSEcCtD
Dapagliflozin—Dizziness—Hydroxyurea—brain cancer	0.000252	0.00364	CcSEcCtD
Dapagliflozin—CYP2D6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00025	0.00482	CbGpPWpGaD
Dapagliflozin—CYP1A1—central nervous system—brain cancer	0.00025	0.00572	CbGeAlD
Dapagliflozin—UGT1A9—Metapathway biotransformation—CYP2C9—brain cancer	0.000249	0.0048	CbGpPWpGaD
Dapagliflozin—CYP1A2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000248	0.00479	CbGpPWpGaD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000247	0.00356	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—brain cancer	0.000245	0.00354	CcSEcCtD
Dapagliflozin—Body temperature increased—Carmustine—brain cancer	0.000243	0.00351	CcSEcCtD
Dapagliflozin—Rash—Hydroxyurea—brain cancer	0.00024	0.00347	CcSEcCtD
Dapagliflozin—Dermatitis—Hydroxyurea—brain cancer	0.00024	0.00346	CcSEcCtD
Dapagliflozin—Headache—Hydroxyurea—brain cancer	0.000239	0.00345	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—brain cancer	0.000238	0.00344	CcSEcCtD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000237	0.00457	CbGpPWpGaD
Dapagliflozin—Infection—Etoposide—brain cancer	0.000237	0.00342	CcSEcCtD
Dapagliflozin—Urticaria—Temozolomide—brain cancer	0.000236	0.00341	CcSEcCtD
Dapagliflozin—Body temperature increased—Temozolomide—brain cancer	0.000235	0.0034	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—brain cancer	0.000231	0.00334	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—brain cancer	0.00023	0.00332	CcSEcCtD
Dapagliflozin—ABCB1—telencephalon—brain cancer	0.000228	0.00523	CbGeAlD
Dapagliflozin—Hypersensitivity—Carmustine—brain cancer	0.000227	0.00328	CcSEcCtD
Dapagliflozin—Nausea—Hydroxyurea—brain cancer	0.000226	0.00327	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—brain cancer	0.000222	0.00321	CcSEcCtD
Dapagliflozin—Hypersensitivity—Temozolomide—brain cancer	0.000219	0.00317	CcSEcCtD
Dapagliflozin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000215	0.00414	CbGpPWpGaD
Dapagliflozin—CYP1A2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000212	0.00408	CbGpPWpGaD
Dapagliflozin—CYP1A1—Oxidative Stress—SOD2—brain cancer	0.00021	0.00405	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPAR Alpha Pathway—CCND1—brain cancer	0.000208	0.00401	CbGpPWpGaD
Dapagliflozin—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—brain cancer	0.000206	0.00397	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Etoposide—brain cancer	0.000206	0.00297	CcSEcCtD
Dapagliflozin—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000206	0.00396	CbGpPWpGaD
Dapagliflozin—Dizziness—Carmustine—brain cancer	0.000204	0.00294	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—brain cancer	0.000204	0.00294	CcSEcCtD
Dapagliflozin—CYP3A4—endocrine gland—brain cancer	0.000203	0.00466	CbGeAlD
Dapagliflozin—CYP2D6—endocrine gland—brain cancer	0.0002	0.00458	CbGeAlD
Dapagliflozin—SLC5A4—Metabolism—CYP2C9—brain cancer	0.000199	0.00384	CbGpPWpGaD
Dapagliflozin—CYP1A1—brain—brain cancer	0.000198	0.00454	CbGeAlD
Dapagliflozin—CYP2D6—head—brain cancer	0.000198	0.00452	CbGeAlD
Dapagliflozin—Dizziness—Temozolomide—brain cancer	0.000197	0.00284	CcSEcCtD
Dapagliflozin—SLC5A2—Disease—HES5—brain cancer	0.000196	0.00378	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HES5—brain cancer	0.000196	0.00378	CbGpPWpGaD
Dapagliflozin—CYP2A6—Biological oxidations—CYP2C9—brain cancer	0.000195	0.00375	CbGpPWpGaD
Dapagliflozin—Rash—Carmustine—brain cancer	0.000194	0.0028	CcSEcCtD
Dapagliflozin—Dermatitis—Carmustine—brain cancer	0.000194	0.0028	CcSEcCtD
Dapagliflozin—Headache—Carmustine—brain cancer	0.000193	0.00279	CcSEcCtD
Dapagliflozin—ABCB1—gonad—brain cancer	0.000191	0.00436	CbGeAlD
Dapagliflozin—Urticaria—Etoposide—brain cancer	0.000189	0.00273	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—brain cancer	0.000188	0.00272	CcSEcCtD
Dapagliflozin—Rash—Temozolomide—brain cancer	0.000188	0.00271	CcSEcCtD
Dapagliflozin—Dermatitis—Temozolomide—brain cancer	0.000187	0.00271	CcSEcCtD
Dapagliflozin—Headache—Temozolomide—brain cancer	0.000186	0.00269	CcSEcCtD
Dapagliflozin—ABCB1—pituitary gland—brain cancer	0.000186	0.00426	CbGeAlD
Dapagliflozin—CYP3A4—central nervous system—brain cancer	0.000183	0.0042	CbGeAlD
Dapagliflozin—Nausea—Carmustine—brain cancer	0.000183	0.00264	CcSEcCtD
Dapagliflozin—CYP2D6—central nervous system—brain cancer	0.00018	0.00413	CbGeAlD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—TRPC6—brain cancer	0.00018	0.00346	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—TRPC6—brain cancer	0.00018	0.00346	CbGpPWpGaD
Dapagliflozin—CYP1A1—Estrogen Receptor Pathway—STAT3—brain cancer	0.00018	0.00346	CbGpPWpGaD
Dapagliflozin—ABCB1—medulla oblongata—brain cancer	0.000179	0.00411	CbGeAlD
Dapagliflozin—Nausea—Temozolomide—brain cancer	0.000177	0.00255	CcSEcCtD
Dapagliflozin—CYP2D6—cerebellum—brain cancer	0.000176	0.00404	CbGeAlD
Dapagliflozin—Hypersensitivity—Etoposide—brain cancer	0.000175	0.00253	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—IDH1—brain cancer	0.000174	0.00335	CbGpPWpGaD
Dapagliflozin—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000174	0.00335	CbGpPWpGaD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000173	0.00334	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—BSG—brain cancer	0.00017	0.00327	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPAR Alpha Pathway—MYC—brain cancer	0.000167	0.00322	CbGpPWpGaD
Dapagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000166	0.00319	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HEY1—brain cancer	0.000165	0.00318	CbGpPWpGaD
Dapagliflozin—ABCB1—midbrain—brain cancer	0.000164	0.00375	CbGeAlD
Dapagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000164	0.00315	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—DLL1—brain cancer	0.000162	0.00312	CbGpPWpGaD
Dapagliflozin—ABCB1—spinal cord—brain cancer	0.00016	0.00366	CbGeAlD
Dapagliflozin—Dizziness—Etoposide—brain cancer	0.000157	0.00227	CcSEcCtD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000154	0.00298	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—CYP2C9—brain cancer	0.000151	0.00291	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—CYP2C9—brain cancer	0.000151	0.00291	CbGpPWpGaD
Dapagliflozin—Rash—Etoposide—brain cancer	0.00015	0.00217	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—brain cancer	0.00015	0.00217	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.00015	0.00288	CbGpPWpGaD
Dapagliflozin—Headache—Etoposide—brain cancer	0.000149	0.00215	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—IDH1—brain cancer	0.000146	0.00281	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—CYP2C9—brain cancer	0.000145	0.00279	CbGpPWpGaD
Dapagliflozin—ABCB1—endocrine gland—brain cancer	0.000144	0.0033	CbGeAlD
Dapagliflozin—CYP2D6—brain—brain cancer	0.000143	0.00328	CbGeAlD
Dapagliflozin—CYP1A1—Metapathway biotransformation—CYP2C9—brain cancer	0.000143	0.00276	CbGpPWpGaD
Dapagliflozin—ABCB1—head—brain cancer	0.000142	0.00325	CbGeAlD
Dapagliflozin—Nausea—Etoposide—brain cancer	0.000141	0.00204	CcSEcCtD
Dapagliflozin—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000141	0.00271	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—SHH—brain cancer	0.000138	0.00265	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—ENO2—brain cancer	0.000138	0.00265	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	0.000135	0.00261	CbGpPWpGaD
Dapagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000134	0.00259	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—IDH1—brain cancer	0.000132	0.00254	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—IDH1—brain cancer	0.000132	0.00254	CbGpPWpGaD
Dapagliflozin—ABCB1—central nervous system—brain cancer	0.00013	0.00297	CbGeAlD
Dapagliflozin—SLC5A2—Metabolism—BSG—brain cancer	0.000129	0.00248	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—BSG—brain cancer	0.000129	0.00248	CbGpPWpGaD
Dapagliflozin—ABCB1—cerebellum—brain cancer	0.000127	0.0029	CbGeAlD
Dapagliflozin—SLC5A1—Disease—HEY1—brain cancer	0.000125	0.00241	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HEY1—brain cancer	0.000125	0.00241	CbGpPWpGaD
Dapagliflozin—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.000125	0.0024	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—DLL1—brain cancer	0.000123	0.00236	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—DLL1—brain cancer	0.000123	0.00236	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CYP2C9—brain cancer	0.000117	0.00225	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—ENO2—brain cancer	0.000115	0.00222	CbGpPWpGaD
Dapagliflozin—CYP1A2—Estrogen Receptor Pathway—STAT3—brain cancer	0.000115	0.00221	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—IDH1—brain cancer	0.000111	0.00213	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—IDH1—brain cancer	0.000111	0.00213	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—CYP2C9—brain cancer	0.000109	0.0021	CbGpPWpGaD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000108	0.00208	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	0.000108	0.00207	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—ENO2—brain cancer	0.000104	0.00201	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ENO2—brain cancer	0.000104	0.00201	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—SHH—brain cancer	0.000104	0.00201	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—SHH—brain cancer	0.000104	0.00201	CbGpPWpGaD
Dapagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	0.000104	0.00199	CbGpPWpGaD
Dapagliflozin—ABCB1—brain—brain cancer	0.000103	0.00236	CbGeAlD
Dapagliflozin—SLC5A4—Disease—VAV1—brain cancer	9.94e-05	0.00192	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—BSG—brain cancer	9.92e-05	0.00191	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	9.7e-05	0.00187	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	9.54e-05	0.00184	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—CYP2C9—brain cancer	9.25e-05	0.00178	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	9.12e-05	0.00176	CbGpPWpGaD
Dapagliflozin—CYP2A6—Fluoropyrimidine Activity—TP53—brain cancer	8.74e-05	0.00168	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—ENO2—brain cancer	8.74e-05	0.00168	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—ENO2—brain cancer	8.74e-05	0.00168	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—RELA—brain cancer	8.63e-05	0.00166	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HES1—brain cancer	8.55e-05	0.00165	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—IDH1—brain cancer	8.53e-05	0.00164	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PDGFRA—brain cancer	8.14e-05	0.00157	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	7.77e-05	0.0015	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—VAV1—brain cancer	7.54e-05	0.00145	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—VAV1—brain cancer	7.54e-05	0.00145	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—PDGFRA—brain cancer	7.38e-05	0.00142	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—IRS2—brain cancer	7.15e-05	0.00138	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP2C9—brain cancer	7.14e-05	0.00137	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	7.09e-05	0.00137	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	7.04e-05	0.00136	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—ENO2—brain cancer	6.74e-05	0.0013	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	6.61e-05	0.00127	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HES1—brain cancer	6.48e-05	0.00125	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HES1—brain cancer	6.48e-05	0.00125	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—APC—brain cancer	6.31e-05	0.00122	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PDGFRA—brain cancer	6.17e-05	0.00119	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PDGFRA—brain cancer	6.17e-05	0.00119	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	6.16e-05	0.00119	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—MYC—brain cancer	6.08e-05	0.00117	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	5.94e-05	0.00115	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—brain cancer	5.94e-05	0.00115	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	5.84e-05	0.00112	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	5.57e-05	0.00107	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	5.5e-05	0.00106	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—IRS2—brain cancer	5.42e-05	0.00104	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—IRS2—brain cancer	5.42e-05	0.00104	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP2C9—brain cancer	5.31e-05	0.00102	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PIK3CG—brain cancer	5.29e-05	0.00102	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	5.1e-05	0.000983	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	4.96e-05	0.000955	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	4.93e-05	0.000949	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—ERBB2—brain cancer	4.9e-05	0.000944	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—APC—brain cancer	4.78e-05	0.000922	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—APC—brain cancer	4.78e-05	0.000922	CbGpPWpGaD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	4.62e-05	0.000889	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—BSG—brain cancer	4.52e-05	0.00087	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP2C9—brain cancer	4.32e-05	0.000832	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CTNNB1—brain cancer	4.29e-05	0.000826	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	4.21e-05	0.000811	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	4.07e-05	0.000784	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	4.05e-05	0.000779	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL2—brain cancer	4.03e-05	0.000776	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PIK3CG—brain cancer	4.01e-05	0.000772	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PIK3CG—brain cancer	4.01e-05	0.000772	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	3.97e-05	0.000764	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	3.95e-05	0.000761	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	3.92e-05	0.000755	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—IDH1—brain cancer	3.89e-05	0.000748	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	3.88e-05	0.000746	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	3.79e-05	0.00073	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	3.79e-05	0.00073	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—STAT3—brain cancer	3.74e-05	0.00072	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—ERBB2—brain cancer	3.72e-05	0.000716	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ERBB2—brain cancer	3.72e-05	0.000716	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—BSG—brain cancer	3.67e-05	0.000707	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	3.64e-05	0.000702	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.55e-05	0.000684	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—MYC—brain cancer	3.47e-05	0.000669	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	3.47e-05	0.000669	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—VEGFA—brain cancer	3.42e-05	0.000659	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—EGFR—brain cancer	3.4e-05	0.000654	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP2C9—brain cancer	3.33e-05	0.000641	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CTNNB1—brain cancer	3.25e-05	0.000626	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CTNNB1—brain cancer	3.25e-05	0.000626	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—IDH1—brain cancer	3.16e-05	0.000608	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CG—brain cancer	3.09e-05	0.000596	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ENO2—brain cancer	3.07e-05	0.000592	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.04e-05	0.000585	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	3e-05	0.000578	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—STAT3—brain cancer	2.83e-05	0.000546	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—STAT3—brain cancer	2.83e-05	0.000546	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—BSG—brain cancer	2.83e-05	0.000545	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	2.82e-05	0.000544	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MYC—brain cancer	2.63e-05	0.000507	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MYC—brain cancer	2.63e-05	0.000507	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.6e-05	0.0005	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EGFR—brain cancer	2.58e-05	0.000496	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EGFR—brain cancer	2.58e-05	0.000496	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.57e-05	0.000495	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ENO2—brain cancer	2.5e-05	0.000481	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP2C9—brain cancer	2.48e-05	0.000478	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—IDH1—brain cancer	2.43e-05	0.000469	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	2.36e-05	0.000454	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	2.19e-05	0.000422	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—BSG—brain cancer	2.11e-05	0.000406	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2C9—brain cancer	1.98e-05	0.000382	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.94e-05	0.000373	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ENO2—brain cancer	1.92e-05	0.000371	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.92e-05	0.00037	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2C9—brain cancer	1.87e-05	0.00036	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—IDH1—brain cancer	1.81e-05	0.000349	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	1.69e-05	0.000325	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—BSG—brain cancer	1.68e-05	0.000324	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—BSG—brain cancer	1.59e-05	0.000306	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2C9—brain cancer	1.58e-05	0.000305	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—BSG—brain cancer	1.57e-05	0.000303	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.55e-05	0.000299	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.52e-05	0.000293	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.48e-05	0.000284	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—IDH1—brain cancer	1.45e-05	0.000279	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ENO2—brain cancer	1.43e-05	0.000276	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CG—brain cancer	1.41e-05	0.000271	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—IDH1—brain cancer	1.37e-05	0.000263	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—IDH1—brain cancer	1.35e-05	0.000261	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BSG—brain cancer	1.34e-05	0.000259	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.28e-05	0.000246	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2C9—brain cancer	1.22e-05	0.000235	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—IDH1—brain cancer	1.16e-05	0.000223	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ENO2—brain cancer	1.15e-05	0.000221	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CG—brain cancer	1.15e-05	0.000221	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.1e-05	0.000212	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO2—brain cancer	1.08e-05	0.000208	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO2—brain cancer	1.07e-05	0.000206	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BSG—brain cancer	1.04e-05	0.0002	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.42e-06	0.000181	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO2—brain cancer	9.14e-06	0.000176	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—IDH1—brain cancer	8.92e-06	0.000172	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—brain cancer	8.83e-06	0.00017	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO2—brain cancer	7.05e-06	0.000136	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—brain cancer	6.58e-06	0.000127	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—brain cancer	5.25e-06	0.000101	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—brain cancer	4.95e-06	9.53e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—brain cancer	4.91e-06	9.45e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—brain cancer	4.19e-06	8.08e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—brain cancer	3.24e-06	6.23e-05	CbGpPWpGaD
